IP Library › Granted Patent US 12,606,607
Granted Patent B2
US 12,606,607 · App. 18/046,408 · Granted Apr 21, 2026

T cell receptors

Inventors: Conor Hayes (Abingdon, GB); Linda Hibbert (Abingdon, GB); Nathaniel Ross Liddy (Abingdon, GB); Tara Mahon (Abingdon, GB); Marine Raman (Abingdon, GB)
Assignee: Immunocore Limited
C07K14/7051A61P35/00C07K16/2833C07K16/30C12N15/62C07K2317/56C07K2317/64C07K2317/92C07K2317/94C07K2319/035
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,606,607
App. No.
18/046,408
Granted
Apr 21, 2026
Kind
B2
Abstract

The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the germline cancer antigen MAGE A4. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGE A4 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.

Claims (18)

1 . A method of treating an HLA-A*02 positive human subject, wherein the human subject has tumor cells that express MAGE A4, comprising administering to the human subject a pharmaceutically effective dose of a pharmaceutical composition comprising a T cell receptor (TCR) together with one or more pharmaceutically acceptable carriers or excipients; wherein the TCR is a soluble TCR comprising a TCR alpha chain variable domain and a TCR beta chain variable domain, wherein the TCR alpha chain variable domain comprises Complementarity Determining Regions (CDRs) of a CDR1 comprising the sequence VSPFSN (SEQ ID NO:6), a CDR2 comprising the sequence LTFSENT (SEQ ID NO:83), and a CDR3 comprising the sequence VVNSAQGLYIPTF (SEQ ID NO:87), and wherein the TCR beta chain variable domain comprises CDRs of a CDR1 comprising the sequence LDHEN (SEQ ID NO:90), a CDR2 comprising the sequence SRFATG (SEQ ID NO:88), and a CDR3 comprising the sequence ASSSDQNSGDPYEQYF (SEQ ID NO:89).

2 . The method according to claim 1 , which further comprises administering separately, in combination, or sequentially, an anti-neoplastic agent.

3 . The method of claim 1 , wherein the tumor cells are from a solid tumor.

4 . The method of claim 1 , wherein the pharmaceutical composition is administered to the human subject by intravenous or direct intratumoral injection.

5 . The method of claim 1 , wherein the TCR alpha chain variable domain comprises at least one of the following mutations with reference to the numbering of SEQ ID NO: 2: C19B and K1A.

6 . The method of claim 1 , wherein the TCR alpha chain variable domain comprises an amino acid sequence corresponding to SEQ ID NO:24, and the TCR beta chain variable domain comprises an amino acid sequence corresponding to SEQ ID NO:29.

7 . The method of claim 1 , wherein the TCR is an alpha-beta heterodimer, having an alpha chain T cell receptor alpha constant (TRAC) domain sequence and a beta chain T cell receptor beta constant 1 or 2 (TRBC1 or TRBC2) domain sequence.

8 . The method of claim 7 , wherein the alpha chain TRAC domain sequence and the beta chain TRBC1 or TRBC2 domain sequence are modified by truncation or substitution to delete a native disulfide bond between Cys4 of exon 2 of TRAC and Cys2 of exon 2 of TRBC1 or TRBC2.

9 . The method of claim 7 , wherein the alpha chain TRAC domain sequence and the beta chain TRBC1 or TRBC2 domain sequence are modified by substitution of cysteine residues for Thr 48 of TRAC and Ser 57 of TRBC1 or TRBC2, said cysteines forming a non-native disulfide bond between the alpha chain constant domain and the beta chain constant domain of the TCR.

10 . The method of claim 1 , wherein the TCR is in a single chain format of the type Vα-L-Vβ, Vβ-L-Vα, Vα-Cα-L-Vβ, or Vα-L-Vβ-Cβ, wherein Vα and Vβ are the TCR α chain variable domain and the TCR β variable domain respectively, Cα and Cβ are a TCR α chain constant domain and a TCR β chain constant domain respectively, and L is a linker sequence.

11 . The method of claim 1 , wherein the TCR is associated with a detectable label, a therapeutic agent, or a pharmacokinetic (PK) modifying moiety.

12 . The method of claim 11 , wherein the therapeutic agent is an anti-CD3 antibody covalently linked to the C-terminus or the N-terminus of the alpha chain or the beta chain of the TCR.

13 . The method of claim 12 , wherein the anti-CD3 antibody is covalently linked to the C-terminus or the N-terminus of the beta chain of the TCR via a linker sequence.

14 . The method of claim 13 , wherein the linker sequence is selected from the group consisting of GGGGS (SEQ ID NO: 30), GGGSG (SEQ ID NO: 31), GGSGG (SEQ ID NO: 32), GSGGG (SEQ ID NO: 33), GSGGGP (SEQ ID NO: 34), GGEPS (SEQ ID NO: 35), GGEGGGP (SEQ ID NO: 36), and GGEGGGSEGGGS (SEQ ID NO: 37).

15 . A method of treating an HLA-A*02 positive human subject, wherein the human subject has tumor cells that express MAGE A4, comprising administering to the subject a pharmaceutically effective dose of a pharmaceutical composition comprising a TCR-anti-CD3 fusion molecule together with one or more pharmaceutically acceptable carriers or excipients; wherein the TCR of the TCR-anti-CD3 fusion molecule comprises a TCR alpha chain comprising a TCR alpha chain variable domain and a TCR beta chain comprising a TCR beta chain variable domain; wherein the TCR alpha chain variable domain comprises the amino acid sequence of SEQ ID NO: 24 and the TCR beta chain variable domain comprises the amino acid sequence of SEQ ID NO: 29, and wherein an anti-CD3 antibody is covalently linked to the N-terminus or the C-terminus of the TCR beta chain via a linker sequence selected from the group consisting of SEQ ID NOs: 30-37.

16 . The method of claim 15 , wherein the TCR alpha chain comprises the amino acid sequence of SEQ ID NO:40, and the TCR beta chain comprises the amino acid sequence of SEQ ID NO:45.

17 . The method of claim 15 , wherein the tumor cells are from a solid tumor.

18 . The method of claim 15 , wherein the pharmaceutical composition is administered to the human subject by intravenous or direct intratumoral injection.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2025
From: HAYES, CONOR; HIBBERT, LINDA; LIDDY, NATHANIEL ROSS; MAHON, TARA; RAMAN, MARINE
To: IMMUNOCORE LIMITED
Reel/Frame 071542/0542 →
Priority Claims (1)
GB 1606009 · Apr 8, 2016 · national
Continuity (2)
Division 16092174
Related Publication 20230322895A1 · Oct 12, 2023
References Cited (120)
US 11505590B2 · Hayes et al. · 2022 [cited by applicant]
US 20070082362A1 · Jakobsen · 2007 [cited by applicant]
US 20090214551A1 · Jakobsen · 2009 [cited by applicant]
US 20090324566A1 · Shiku · 2009 [cited by applicant]
US 20130109053A1 · Macdonald · 2013 [cited by applicant]
US 20140371085A1 · Jakobsen · 2014 [cited by applicant]
US 20140378389A1 · Robbins · 2014 [cited by applicant]
US 20190092834A1 · Hayes · 2019 [cited by applicant]
CO 20170010502A2 · 2018 [cited by applicant]
CO 20180010453A2 · 2018 [cited by applicant]
CO 20180010811A2 · 2018 [cited by applicant]
WO WO9839482A1 · 1998 [cited by applicant]
WO 199918129A1 · 1999 [cited by applicant]
WO 2000020445A2 · 2000 [cited by applicant]
WO 2000020445A3 · 2000 [cited by applicant]
WO 200148145A2 · 2001 [cited by applicant]
WO WO0162908A2 · 2001 [cited by applicant]
WO 200148145A3 · 2002 [cited by applicant]
WO 2003020763A2 · 2003 [cited by applicant]
WO 2003020763A3 · 2003 [cited by applicant]
WO 2004023973A2 · 2004 [cited by applicant]
WO WO2004023974A2 · 2004 [cited by applicant]
WO 2004033685A1 · 2004 [cited by applicant]
WO WO2004044004A2 · 2004 [cited by applicant]
WO 2004023973A3 · 2004 [cited by applicant]
WO 2004074322A1 · 2004 [cited by applicant]
WO WO2007032255A1 · 2007 [cited by applicant]
WO 2010133828A1 · 2010 [cited by applicant]
WO 2013053021A1 · 2013 [cited by applicant]
WO 2014096803A1 · 2014 [cited by applicant]
WO 2014118236A2 · 2014 [cited by applicant]
WO 2014118236A3 · 2014 [cited by applicant]
WO 2014160030A2 · 2014 [cited by applicant]
WO 2014160030A3 · 2014 [cited by applicant]
WO 2016007570A2 · 2016 [cited by applicant]
WO 2016022400A1 · 2016 [cited by applicant]
WO 2016007570A3 · 2016 [cited by applicant]
WO WO2020157211A1 · 2020 [cited by applicant]
Weon et al., Current Opinion in Cell Biology 2015, 37:1-8. (Year: 2015). [cited by examiner]
NCT03132922, pp. 1-9, Jan. 22, 2024. (Year: 2024). [cited by examiner]
NCT05129280, pp. 1-7, Aug. 4, 2023. (Year: 2023). [cited by examiner]
Wang et al. (Molecular Therapy: Methods & Clinical Development vol. 32 Jun. 2024, p. 1-11). (Year: 2024). [cited by examiner]
Aleksic, M. et al. (2012). “Different Affinity Windows For Virus And Cancer-Specific T-Cell Receptors: Implications For Therapeutic Strategies,” Eu J Immunol. 42(12):3174-3179. [cited by applicant]
Altschul, S.F. et al. (Oct. 5, 1990). “Basic Local Alignment Search Tool,” J. Mol. Biol. 215(3):403-410. [cited by applicant]
Altschul, S.F .et al. (Sep. 1, 1997). “Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs,” Nucleic Acids Res. 25(17):3389-3402. [cited by applicant]
Arstila, T.P. et al. (Oct. 29, 1999). “A Direct Estimate Of The Human αβ T Cell Receptor Diversity,” Science 286 (5441):958-961. [cited by applicant]
Bedquelle, H. et al. (Jan. 2006). “Diversity and Junction Residues As Hotspots of Binding Energy In an Antibody Neutralizing The Dengue Virus,” FEBS J. 273(1):34-46. [cited by applicant]
Bergeron, A. et al. (2009, e-pub. Apr. 14, 2009). “High Frequency Of MAGE-A4 and MAGE-A9 Expression In High-Risk Bladder Cancer,” Int J Cancer 125(6):1365-1371. [cited by applicant]
Bossi, G. (May 2014, e-pub. Feb. 15, 2014). “ImmTAC-Redirected Tumour Cell Killing Induces and Potentiates Antigen Cross-Presentation By Dendritic Cells,” Cancer Immunology, Immunotherapy 63(5):437-448. [cited by applicant]
Bossi, G. et al. (Nov. 2013). “Examining The Presentation Of Tumor-Associated Antigens On Peptide-Pulsed T2 Cells,” Oncolummunology 12(11):e26840, 7 pages. [cited by applicant]
Boulter, J.M. et al. (2003). “Stable, Soluble T-Cell Receptor Molecules For Crystallization and Therapeutics,” Protein Eng 16(9):707-711. [cited by applicant]
Brown, M. et al. (May 1, 1996). “Tolerance of Single, But Not Multiple, Amino Acid Replacements in Antibody VH CDR 2: A Means of Minimizing B Cell Wastage From Somatic Hypermutation?,” J. Immunol. 156(9):3285-3291. [cited by applicant]
Cabezón, T et al. (2013). “Proteomic Profiling of Triple-Negative Breast Carcinomas in Combination With a Three-tier Orthogonal Technology Approach Identifies Mage-A4 as Potential Therapeutic Target in Estrogen Receptor… [cited by applicant]
Cameron, B.J. et al. (Aug. 7, 2013). “Identification of a Titin-Derived HLA-A1-Presented Peptide As A Cross-Reactive Target For Engineered MAGE A3-Directed T Cells,” Sci Trans Med. 5(197):197ra103, 24 pages. [cited by applicant]
CAT. No. MHC-LC1146 “APC-A*02:01/Human MAGEA4 (GVYDGREHTV) MHC Tetramer,” retrieved from https://www.creativeblolabs.net/pdf/MHC-LC1146.pdf, 2 pages. [cited by applicant]
Chen, X. et al. (Oct. 15, 2013). “Fusion Protein Linkers: Property, Design and Functionality,” Advanced Drug Delivery Reviews 65(10):1357-1369, 32 pages. [cited by applicant]
Chervin, A.S. et al. (Dec. 31, 2008). “Engineering Higher Affinity T Cell Receptors Using A T Cell Display System,” J. Immuno. Methods 339(2):175-184, 21 pages. [cited by applicant]
Colman, P.M. (1994). “Effects Of Amino Acid Sequence Changes On Antibody-Antigen Interactions,” Research in Immunology 145(1):33-36. [cited by applicant]
Cuffel, C. et al. (2011). “Pattern and Clinical Significance Of Cancer-Testis Gene Expression in Head and Neck Squamous Cell Carcinoma,” Int J Cancer 128(11):2625-2634. [cited by applicant]
Cunha-Neto, E. (Feb. 1999). “MHC-Restricted Antigen Presentation and Recognition: Constraints On Gene, Recombinant and Peptide Vaccines in Humans,” Brazilian Journal of Medical and Biological Research 32:199-205. [cited by applicant]
Davis, M.M. et al. (Apr. 1998). “Ligand Recognition by αβ T Cell Receptors,” Annu Rev Immunol 16:(15):523-544. [cited by applicant]
De La Hera, A. et al. (1991). “Structure of the T Cell Antigen Receptor (TCR): Two CD3 Epsilon Subunits in a Functional TCR/CD3 Complex,” The Journal of Experimental Medicine 173(1):7-17. [cited by applicant]
De Plaen, E. et al. (1994). “Structure, Chromosomal Localization, and Expression Of 12 Genes Of the MAGE Family,” Immunogenetics 40(5):360-369. [cited by applicant]
Dennis, M.S. et al. (Sep. 20, 2002). “Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins,” J Biol Chem 277(38):35035-35043. [cited by applicant]
Devereux, J. et al. (1984). “A Comprehensive Set Of Sequence Analysis Programs for the VAX,” Nucleic Acids Research 12(1):387-395. [cited by applicant]
Dozier, J.K. et al. (Oct. 28, 2015). “Site-Specific PEGylation of Therapeutic Proteins,” Int J Mol Sci. 16(10):25831-25864. [cited by applicant]
Duffour, M.-T. et al. (1999). “A MAGE-A4 Peptide Presented by HLA-A2 is Recognized by Cytolytic T Lymphocytes,” Eur J Immunol 29(10):3329-3337. [cited by applicant]
Epel, M. et al. (Nov. 2002, e-pub. Sep. 13, 2002). “A Functional Recombinant Single-Chain T Cell Receptor Fragment Capable Of Selectively Targeting Antigen-Presenting Cells,” Cancer Immunol immunother. 51(10):565-573. [cited by applicant]
Folch, G. et al. (2000). “The Human T Cell Receptor Beta Diversity (TRBD) and Beta Joining (TRBJ) Genes,” Exp Clin Immunogenet 17(2):107-114. [cited by applicant]
Folch, G. et al. (2000). “The Human T cell Receptor Beta Variable (TRBV) Genes,” Exp Clin Immunogenet 17(1):42-54. [cited by applicant]
Forghanifard, M.M. et al. (Aug. 1, 2011). “Cancer-Testis Gene Expression Profiling In Esophageal Squamous Cell Carcinoma: Identification Of Specific Tumor Marker And Potential Targets For Immunotherapy,” Cancer Biol The… [cited by applicant]
Garboczi, D.N. et al. (Apr. 1992). “HLA-A2-Peptide Complexes: Refolding and Crystallization Of Molecules Expressed In [cited by applicant]
Gasser, B. et al. (Feb. 2007). “Antibody Production With Yeasts and Filamentous Fungi: On the Road to Large Scale?,” Biotechnology Letters 29(2):201-212. [cited by applicant]
Holler, P.D. et al. (May 9, 2000). “In vitro Evolution Of A T Cell Receptor With High Affinity For Peptide/MHC,” Proc Natl Acad Sci USA 97(10):5387-5392. [cited by applicant]
Inaguma, Y. et al. (Jun. 2014, e-pub. Apr. 3, 2014). “Construction and Molecular Characterization of a T-Cell Receptor-Like Antibody and CAR-T Cells Specific For Minor Histocompatibility Antigen HA-1H,” Gene Therapy 21 … [cited by applicant]
International Preliminary Report on Patentability, issued Oct. 9, 2018, for PCT Application No. PCT/GB2017/050985, filed Apr. 7, 2017, 7 pages. [cited by applicant]
International Search Report and Written Opinion of the International Search Authority, mailed Jun. 19, 2017, for PCT Application No. PCT/GB2017/050985, filed Apr. 7, 2017, 14 pages. [cited by applicant]
Jefferis, R. (Mar. 2009). “Glycosylation As A Strategy To Improve Antibody-Based Therapeutics,” Nat Rev Drug Discov 8(3):226-234. [cited by applicant]
Jevsevar, S. et al. (Jan. 2010). “PEGylation Of Therapeutic Proteins,” Biotechnol J. 5(1):113-128, 52 pages. [cited by applicant]
June, C.H. et al. (Sep. 2014). “Engineered T Cells For Cancer Therapy,” Cancer Immunol Immunother 63 (9):969-975, 11 pages. [cited by applicant]
Karimi, S. et al. (May 2012). “Characterization of Melanoma-Associated Antigen-A Genes Family Differential Expression in Non-Small-Cell Lung Cancers,” Clin Lung Cancer 13(3):214-219. [cited by applicant]
Karlin, S. et al. (Jun. 1993). “Applications and Statistics For Multiple High-Scoring Segments In Molecular Sequences,” Proc. Natl. Acad. Sci. USA 90:5873-5877. [cited by applicant]
Karlin, S et al. (Mar. 1990). “Methods For Assessing The Statistical Significance Of Molecular Sequence Features By Using General Scoring Schemes,” Proc. Natl. Acad. Scl. USA 87(6):2264-2268. [cited by applicant]
Lefranc, M.P. (2003). “IMGT® Databases, Web Resources And Tools For Immunoglobulin and T Cell Receptor Sequence Analysis, http://imgt.cines.fr,” Leukemia 17(1):260-266. [cited by applicant]
Li, Y. et al. (Mar. 2005, e-pub. Feb. 20, 2005). “Directed Evolution Of Human T-Cell Receptors With Picomolar Affinities By Phage Display,” Nat Biotechnol. 23(3):349-354. [cited by applicant]
Liddy, N. et al. (Jun. 2012). “Monoclonal TCR-Redirected Tumor Cell Killing,” Nat Med 18(6):980-987. [cited by applicant]
Lissin, N.M. et al. (2013). “Chapter 32—High-Affinity Monocloncal T-Cell Receptor (mTCR) Fusions,” Fusion Protein Technologies for Biophamaceuticals: Applications and Challenges, 11 pages. [cited by applicant]
Maeda, Y. et al. (Jul. 1, 1997). “Engineering of Functional Chimeric Protein G-Vargula Luciferase,” Analytical Biochemistry 249(2):147-152. [cited by applicant]
Maus, M.V. et al. (Jul. 2013). “T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans,” Cancer Immunology Research 1(1):26-31. [cited by applicant]
Muller, S. et al. (Dec. 2008). “Spliceosomal Peptide P140 for Immunotherapy of Systemic Lupus Erthematosus: Results of an Early Phase II Clinical Trial.” Arthritis & Rheumatism: Offical Journal of the American College o… [cited by applicant]
Nazarov, V.I. (2015). “Review of Analysis Methods, Generation Models and Repertoire Selection Models Immune Receptor,” New Information Technology in Automated Systems 18:270-280. English Abstract. [cited by applicant]
Non-Final Office Action, mailed Mar. 3, 2022, for U.S. Appl. No. 16/092,174, filed Oct. 8, 2018, 13 pages. [cited by applicant]
O'Callaghan, C.A. et al. (1999). “BirA Enzyme: Production and Application in the Study of Membrane Receptor ±Ligand Interactions by Site-Specific Biotinylation,” Anal Biochem 266(1):9-15. [cited by applicant]
Oates, M.E. et al. (2013, e-pub. Nov. 29, 2012). “D [cited by applicant]
Pearson, W.R. et al. (Apr. 1988). “Improved Tools For Biological Sequence Comparison,” Proc. Natl. Acad. Sci. USA 85(8):2444-2448. [cited by applicant]
Purbhoo. M.A. et al. (2006). “Quantifying and Imaging NY-ESO-1/LAGE-1-Derived Epitopes on Tumor Cells Using High Affinity T Cell Receptors,” J Immunol 176(12):7308-7316. [cited by applicant]
Rashtchian, A. (Feb. 1995). “Novel Methods For Cloning and Engineering Genes Using The Polymerase Chain Reaction,” Curr Opin Biotechnol 6(1):30-36. [cited by applicant]
Robbins, P.F. et al. (2008). “Single and Dual Amino Acid Substitutions in TOR CDRs Can Enhance Antigen-Specific T Cell Functions,” J Immunol. 180:6116-6131. [cited by applicant]
Robins, H.S. et al. (Nov. 5, 2009, e-pub. Aug. 25, 2009). “Comprehensive Assessment Of T-Cell Receptor β-Chain Diversity In αβ T Cells,” Blood 114(19):4099-4107, 20 pages. [cited by applicant]
Rosenberg, S.A. et al. (Apr. 2008). “Adoptive Cell Transfer: A Clinical Path To Effective Cancer Immunotherapy,” Nat Rev Cancer 8(4):299-308, 22 pages. [cited by applicant]
Rudikoff, S. et al. (Mar. 1982). “Single Amino Acid Substitution Altering Antigen-Binding Specificity,” Proc. Natl. Acad. Sci. USA 79:1979-1983. [cited by applicant]
Sambrook, J. et al. (1989). Molecular Cloning—A Laboratory Manual, 2nd Edition, Maniatis, T.(ed.) et al., Cold Spring Harbor Laboratory Press, New York, NY pp. v-xxxii, 28 pages, (Table of Contents only). [cited by applicant]
Sambrook, J. et al. (2001). Molecular Cloning: A Laboratory Manual Cold Spring Harbor Laboratory Press, Cold Spring Harbor,N.Y., 3rd ed., 1 page, Table of Contents. [cited by applicant]
Scaviner, D. et al. (2000). “The Human T Cell Receptor Alpha Joining (TRAJ) Genes,” Exp Clin Immunogenet 17 (2):97-106. [cited by applicant]
Scaviner, D. et al. (2000). “The Human T Cell Receptor Alpha Variable (TRAV) Genes,” Exp Clin Immunogenet 17(2):83-96. [cited by applicant]
Schellenberger, V. et al. (Dec. 2009, e-pub. Nov. 15, 2009). “A Recombinant Polypeptide Extends The in vivo Half-Life Of Peptides And Proteins In A Tunable Manner,” Nat Biotechnol. 27(12):1186-1190. [cited by applicant]
Schlapschy, M. et al. (Aug. 2013, e-pub. Jun. 10, 2013). “PASylation: A Biological Alternative To PEGylation For Extending The Plasma Half-Life Of Pharmaceutically Active Proteins,” Protein Eng Des Sel. 26(8):489-501. [cited by applicant]
Sinclair, A.M. et al. (Aug. 2005). “Glycoengineering: The Effect Of Glycosylation On The Properties Of Therapeutic Proteins,” Pharm Sci. 94(8):1626-1635. [cited by applicant]
Singapore Written Opinion; dated Jan. 9, 2020, for Singapore Patent Application No. 11201808797X, filed Apr. 7, 2017, 6 pages. [cited by applicant]
Svobodová, S. et al. (Feb. 2011. E-pub. Nov. 4, 2010). “Cancer-Testis Antigen Expression In Primary Cutaneous Melanoma Has Independent Prognostic Value Comparable To That Of Breslow Thickness, Ulceration and Mitotic Rat… [cited by applicant]
Teplyakov, A. et al. (2014, e-pub. Mar. 31, 2014). “Antibody Modeling Assessment II. Structures and Models,” Proteins: Structure, Function, and Bioinformatics 82(8):1563-1582. [cited by applicant]
Torelli, A. et al. (Feb. 1994). “Advance and Adam: Two Algorithms For The Analysis Of Global Similarity Between Homologous Informational Sequences,” Comput. Appl. Biosci. 10(1):3-5. [cited by applicant]
Vajdos, F. et al. (2002) “Comprehensive Functional Maps of the Antigen Binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis,” J. Mol. Biol. 320:415-428. [cited by applicant]
Weidanz, J.A. et al. (Dec. 1, 1998). “Display Of Functional αβ Single-Chain T-Cell Receptor Molecules On The Surface Of Bacteriophage,” J Immunol Methods. 221(1-2):59-76. [cited by applicant]
Willuda, J. et al. (Apr. 2001). “Tumor Targeting of Mono-, Di-, and Tetravalent Anti-p185HER-2 Miniantibodies Multimerized by Self-associating Peptides,” J. Biol. Chem. 276(17):14385-14392. [cited by applicant]
Wilson, D.B. et al. (Feb. 2004). “Specificity and Degeneracy Of T Cells,” Mol Immunol 40(14-15):1047-1055. [cited by applicant]
Wooldridge, L. et al. (Jan. 6, 2012). “A Single Autoimmune T Cell Receptor Recognizes More Than a Million Different Peptides,” J Biol Chem 287(2):1168-1177. [cited by applicant]
Yakirevich, E. et al. (Dec. 15, 2003). “Expression MAGE-A4 and NY-ESO_1 Cancer-Testis Antigens in Serous Ovarian Neoplasms,” Clinical Cancer Research 9(17):6453-6460. [cited by applicant]
Zhao, Y. et al. (2007). “High-Affinity TCRs Generated by Phage Display Provide CD4+ T Cells with the Ability to Recognize and Kill Tumor Cell Lines,” J. Immunol, 179(9):5845-5854. [cited by applicant]
Lee, K.-D. et al., “Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2,” Oncol Rep. 15(5), 2006, pp. 1211-1216. [cited by applicant]